Our Clinical Trials
Clinical trials are an important part of bringing new treatments to patients. By participating in a clinical trial, participants can gain access to new research treatments before they are widely available and help others by contributing to important medical research. Axovant is committed to providing treatments for all aspects of dementia, and a list of our current clinical trials can be found below.
ONGOING CLINICAL TRIALS
In January 2016, Axovant began recruiting for a Phase 2b clinical trial of intepirdine (RVT-101) in patients with dementia with Lewy bodies called the HEADWAY-DLB study.
In October 2015, Axovant began enrollment in the Phase 3 MINDSET clinical trial. MINDSET is evaluating intepirdine (RVT-101) for mild-to-moderate Alzheimer’s disease. Learn More…
In September 2016, we initiated a Phase 2 clinical trial of intepirdine (RVT-101) to evaluate its effects on gait and balance in patients with Alzheimer’s disease, DLB and Parkinson’s disease dementia.
In March 2016, we initiated a Phase 2 clinical trial that is evaluating nelotanserin for the treatment of subjects with DLB or Parkinson’s disease dementia who have REM Sleep Behavior Disorder.
In December 2015, Axovant began recruiting for a Phase 2 clinical trial which is evaluating nelotanserin for the treatment of visual hallucinations in patients with Lewy body dementia. To learn more, please contact us at firstname.lastname@example.org.